1-(5-Methylpyrimidin-2-YL)ethan-1-amine | 944906-27-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-(5-Methylpyrimidin-2-YL)ethan-1-amine
• 英文别名: 1-(5-methylpyrimidin-2-yl)ethanamine
• CAS: 944906-27-8
• 化学式: C₇H₁₁N₃
• 分子量: 137.18
• InChiKey: RWYXPAGTGSPMBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
  申请人：Karyopharm Therapeutics, Inc.

  公开号：EP2736883A1

  公开（公告）日：2014-06-04
• Nuclear Transport Modulators And Uses Thereof
  申请人：Karyopharm Therapeutics Inc.

  公开号：US20170137430A1

  公开（公告）日：2017-05-18

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
• US9428490B2
  申请人：——

  公开号：US9428490B2

  公开（公告）日：2016-08-30
• [EN] NUCLEAR TRANSPORT MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE TRANSPORT NUCLÉAIRE ET LEURS UTILISATIONS
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2013019561A1

  公开（公告）日：2013-02-07

  The invention generally relates to nuclear transport modulators, e.g CRM1inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.